Columbus Circle Investors purchased a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 51,997 shares of the biopharmaceutical company’s stock, valued at approximately $2,606,000. Columbus Circle Investors owned 0.20% of Esperion Therapeutics at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 4,856 shares during the period. Aperio Group LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $249,000. SG Americas Securities LLC lifted its holdings in shares of Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,991 shares during the period. Voya Investment Management LLC lifted its holdings in shares of Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares during the period. Finally, US Bancorp DE lifted its holdings in shares of Esperion Therapeutics by 1.1% during the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 104 shares during the period. 92.27% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on ESPR. Chardan Capital increased their price target on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Northland Securities reissued a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Deutsche Bank set a $64.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $60.15.
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) traded up $1.53 during mid-day trading on Thursday, hitting $54.67. The stock had a trading volume of 723,416 shares, compared to its average volume of 1,023,997. Esperion Therapeutics, Inc. has a twelve month low of $10.71 and a twelve month high of $65.20.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter last year, the firm posted ($0.77) earnings per share. sell-side analysts forecast that Esperion Therapeutics, Inc. will post -7.21 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/07/columbus-circle-investors-invests-2-61-million-in-esperion-therapeutics-inc-espr-stock.html.
Esperion Therapeutics Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.